Krystal Biotech, Inc.
Financials
Valuation Metrics
Krystal Biotech, Inc.'s Market Cap is $9.92B. At end of 2025 it was $7.14B. Ranked #922 of 3,121 in US market (top 30%), #294 of 1,463 on NASDAQ (top 20%), #45 of 266 in Pharmaceuticals, Biotechnology & Life Sciences (top 17%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $9.92B | US#922/3,121 Sec#45/266 |
| Revenue | $440M | US#2,322/3,121 Sec#83/266 |
| Net Income | $241M | US#1,198/3,121 Sec#38/266 |
| Total Assets | $1.50B | US#2,264/3,121 Sec#68/266 |
| Net Assets | $1.36B | US#1,545/3,121 Sec#46/266 |
| Employees | 295 | US#2,425/3,121 Sec#112/266 |
| Value | ||
| P/E | 41.10x | US#1,825/3,121 Sec#50/266 |
| P/B | 7.30x | US#2,469/3,121 Sec#173/266 |
| PEG | 0.64x | US#706/3,121 Sec#23/266 |
| P/S | 22.53x | US#2,862/3,121 Sec#146/266 |
| EV/EBITDA | 43.52x | US#2,341/3,121 Sec#70/266 |
| FCF Yield | 2.60% | US#1,929/3,121 Sec#62/266 |
| Profitability | ||
| ROE | 17.77% | US#712/3,121 Sec#37/266 |
| ROA | 16.09% | US#194/3,121 Sec#22/266 |
| Op. Margin | 44.93% | US#186/3,121 Sec#9/266 |
| Revenue Growth | 22.63% | US#614/3,121 Sec#72/266 |
| Earnings Growth | 64.57% | US#416/3,121 Sec#20/266 |
| Financial Health | ||
| Debt Ratio | 10.41% | US#115/3,121 Sec#51/266 |
| Total Debt | $9M | US#2,847/3,121 Sec#204/266 |
| FCF | $258M | US#1,252/3,121 Sec#41/266 |
| Cash | $428M | US#1,172/3,121 Sec#63/266 |
| Current Ratio | 8.32x | US#311/3,121 Sec#95/266 |
| Net Debt/EBITDA | -1.92x | US#178/3,121 Sec#15/266 |
| Performance | ||
| 1Y Return | 109.62% | US#157/3,121 Sec#55/266 |
| 1M Return | -1.94% | US#745/3,121 Sec#77/266 |
| From 52W High | -11.99% | US#834/3,121 Sec#57/266 |
| 1Y MDD | -17.34% | US#505/3,121 Sec#16/266 |
| Trading | ||
| Volume | 748,195 shares | US#2,464/3,121 Sec#237/266 |
| Trading Value | $253M | US#869/3,121 Sec#59/266 |
| Per Share | ||
| EPS | $8.19 | US#383/3,121 Sec#11/266 |
| BPS | $46.10 | US#493/3,121 Sec#10/266 |
Company Info
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB803 for ocular complications of dystrophic epidermolysis bullosa; KB801 for neurotrophic keratitis; KB407, which is in Phase 1 clinical trials for treating cystic fibrosis; KB111 for Hailey-Hailey disease; KB707 for solid tumors; KB304 for dynamic wrinkles; KB707 that is in Phase 1/2 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.